EXAGEN INC. Cash and Equivalents

Quick Answer

EXAGEN INC. reported Cash and Equivalents of $32.22 million for fiscal year 2025.

EXAGEN INC. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $32.22M +46.2%
2024 $22.04M -39.6%
2023 $36.49M -41.5%
2022 $62.39M -37.3%
2021 $99.44M +73.1%
2020 $57.45M -20.3%
2019 $72.08M +447.6%
2018 $13.16M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2025 $35.65M +61.8% +18.7%
June 30, 2025 $30.03M +22.7% +168.3%
March 31, 2025 $11.19M -58.9% -49.2%
December 31, 2024 $22.04M -39.6% +0.0%
September 30, 2024 $22.04M -22.5% -10.0%
June 30, 2024 $24.48M -22.2% -10.2%
March 31, 2024 $27.27M -47.7% -25.3%
December 31, 2023 $36.49M -41.5% +28.3%
  • EXAGEN INC. showed an increase of +46.2% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2018–2025 period, EXAGEN INC.’s cash and equivalents has grown by 144.8% (from $13.16 million to $32.22 million).
  • The most recent figure is from EXAGEN INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment